Johanna Wennerblom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johanna Wennerblom has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Bobby Tingstedt
Department of Surgery, Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden
5 shared publications Caroline Williamsson
Department of Surgery, Lund University, Skåne University Hospital at Lund , Lund
3 shared publicationsChristina Biörserud
Department of Surgery , Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden
3 shared publicationsErnesto Sparrelid
Department of Clinical Science, Intervention, and Technology Karolinska Institute Stockholm Sweden
3 shared publicationsPoya Ghorbani
Department of Clinical Science, Intervention, and Technology Karolinska Institute Stockholm Sweden
3 shared publications- Aki Uutela
Hepatobiliary and Pancreatic Unit & Edinburgh Transplant Unit, University of Edinburgh, Royal Infirmary , Edinburgh
2 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (3) , e70199
Survival After Pancreatic Resection for Intraductal Papillary Mucinous Neoplasm: Supporting Selective Surgery
Introduction: Resection of intraductal papillary mucinous neoplasm (IPMN) aims to prevent progression to invasive pancreatic cancer. However, the risks of pancreatic surgery and frequent findings of low‐grade dysplasia (LGD) raise concerns about overtreatment. This EAHPBA‐endorsed multinational study evaluated short‐ and long‐term overall survival (OS) following preventive resection for IPMN (without pre‐operative signs of cancer). Methods: Adult patients with resected IPMN showing LGD, high grade dysplasia (HGD) or T1‐staged invasive carcinoma from 2008–2023 were identified from the OPTIMAL‐IPMN database. Estimated OS rates at one, five and 10 years in patients undergoing preventive pancreatic resection were assessed using Kaplan‐Meier analyses and predictors for mortality were evaluated using parametric survival regressions. Results: Among 2275 patients in the OPTIMAL‐IPMN database, 1728 (77%) had undergone preventive pancreatic resection for IPMN. Of those were 61% resected without prior surveillance. Final pathology revealed LGD in 63%, HGD in 27% and T1a‐c‐staged invasive cancer in 10% (7.3% T1a‐b, 2.8% T1c). Estimated 1‐year OS rate was 97%. Estimated 5‐year OS rates (landmark analysis at 1 year) for LGD, HGD, T1a‐b, and T1c was 97%, 99%, 96% and 91% respectively. Independent predictors for long‐term mortality included age ≥ 75 versus < 75 years (HR 1.97) and T1c versus LGD (HR 8.12). Conclusion: This multinational study confirms excellent survival after preventive IPMN resection but reveals many upfront resections yielding LGD with unknown survival benefit. Future studies should aim to determine which patients can be followed safely with monitoring to avoid unnecessary immediate resection.
- 24 March 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (3) , e70199
Open AccessSurvival After Pancreatic Resection for Intraductal Papillary Mucinous Neoplasm: Supporting Selective Surgery
Introduction: Resection of intraductal papillary mucinous neoplasm (IPMN) aims to prevent progression to invasive pancreatic cancer. However, the risks of pancreatic surgery and frequent findings of low‐grade dysplasia (LGD) raise concerns about overtreatment. This EAHPBA‐endorsed multinational study evaluated short‐ and long‐term overall survival (OS) following preventive resection for IPMN (without pre‐operative signs of cancer). Methods: Adult patients with resected IPMN showing LGD, high grade dysplasia (HGD) or T1‐staged invasive carcinoma from 2008–2023 were identified from the OPTIMAL‐IPMN database. Estimated OS rates at one, five and 10 years in patients undergoing preventive pancreatic resection were assessed using Kaplan‐Meier analyses and predictors for mortality were evaluated using parametric survival regressions. Results: Among 2275 patients in the OPTIMAL‐IPMN database, 1728 (77%) had undergone preventive pancreatic resection for IPMN. Of those were 61% resected without prior surveillance. Final pathology revealed LGD in 63%, HGD in 27% and T1a‐c‐staged invasive cancer in 10% (7.3% T1a‐b, 2.8% T1c). Estimated 1‐year OS rate was 97%. Estimated 5‐year OS rates (landmark analysis at 1 year) for LGD, HGD, T1a‐b, and T1c was 97%, 99%, 96% and 91% respectively. Independent predictors for long‐term mortality included age ≥ 75 versus < 75 years (HR 1.97) and T1c versus LGD (HR 8.12). Conclusion: This multinational study confirms excellent survival after preventive IPMN resection but reveals many upfront resections yielding LGD with unknown survival benefit. Future studies should aim to determine which patients can be followed safely with monitoring to avoid unnecessary immediate resection.
- Top Cited PapersOpen Access
- 11 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 9884-9895
Oncologic multivisceral resections involving the pancreas: Short-term outcomes and risk-analysis
Objective: To evaluate short-term outcomes and identify predictors of morbidity and mortality following multivisceral oncologic resections involving the pancreas. Summary background data: Multivisceral resections including the pancreas are required for locally advanced abdominal malignancies but are associated with considerable perioperative risk. While smaller series suggest acceptable outcomes in selected patients, large-scale international data are lacking to guide surgical decision-making and risk stratification. Methods: This was a retrospective cohort study of 1283 patients from 31 international centers who underwent multivisceral oncologic resections involving the pancreas. Patient demographics, tumor characteristics, operative details, and 90-day postoperative outcomes were analyzed. Results: The cohort had a mean age of 64.7 years, and 54.7% were male. Distal pancreatectomy was the most frequent procedure (60.5%), and R0 resection was achieved in 60.9% of cases. The 90-day mortality was 6.9%, highest in patients with gastric adenocarcinoma (16.7%). Major complications (Clavien–Dindo grade III–V) occurred in 34.4% of patients. Higher ASA classification and open surgical approach were independently associated with increased morbidity and mortality. Prolonged operative time was associated with morbidity only. Female gender and treatment at high-volume centers were protective. In patients with pancreatic tumors, resection involving the colon (OR: 1.78, P < 0.001), stomach (OR: 1.33, P = 0.042), or three or more organs (OR: 1.75, P = 0.006) significantly increased complication rates. Conclusions: Multivisceral resections involving the pancreas are associated with relevant perioperative risk. Optimizing patient selection, favoring minimally invasive techniques when feasible in selected patients, and centralizing care to high-volume centers may help improve outcomes for these complex surgical procedures.
- 11 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 9884-9895
Top Cited PapersOpen AccessOncologic multivisceral resections involving the pancreas: Short-term outcomes and risk-analysis
Objective: To evaluate short-term outcomes and identify predictors of morbidity and mortality following multivisceral oncologic resections involving the pancreas. Summary background data: Multivisceral resections including the pancreas are required for locally advanced abdominal malignancies but are associated with considerable perioperative risk. While smaller series suggest acceptable outcomes in selected patients, large-scale international data are lacking to guide surgical decision-making and risk stratification. Methods: This was a retrospective cohort study of 1283 patients from 31 international centers who underwent multivisceral oncologic resections involving the pancreas. Patient demographics, tumor characteristics, operative details, and 90-day postoperative outcomes were analyzed. Results: The cohort had a mean age of 64.7 years, and 54.7% were male. Distal pancreatectomy was the most frequent procedure (60.5%), and R0 resection was achieved in 60.9% of cases. The 90-day mortality was 6.9%, highest in patients with gastric adenocarcinoma (16.7%). Major complications (Clavien–Dindo grade III–V) occurred in 34.4% of patients. Higher ASA classification and open surgical approach were independently associated with increased morbidity and mortality. Prolonged operative time was associated with morbidity only. Female gender and treatment at high-volume centers were protective. In patients with pancreatic tumors, resection involving the colon (OR: 1.78, P < 0.001), stomach (OR: 1.33, P = 0.042), or three or more organs (OR: 1.75, P = 0.006) significantly increased complication rates. Conclusions: Multivisceral resections involving the pancreas are associated with relevant perioperative risk. Optimizing patient selection, favoring minimally invasive techniques when feasible in selected patients, and centralizing care to high-volume centers may help improve outcomes for these complex surgical procedures.
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Scandinavian Journal of Pain
- Vol. 26 (1)
Analgesic patterns and predictors of opioid consumption following epidural analgesia discontinuation after pancreatic cancer surgery
Introduction: Thoracic epidural analgesia (EDA) is recommended for multimodal perioperative pain management. However, increased pain and opioid consumption are frequently observed following EDA discontinuation. Risk factors for this transition phase remain poorly characterized after pancreatic surgery. Aim: The primary aim was to characterize analgesic strategies, including opioid consumption and use of non-opioid agents, following EDA discontinuation after pancreatic cancer surgery (days 0–2). The secondary aim was to determine predictors of increased opioid consumption on the day of EDA discontinuation (day 0). Methods: In this retrospective cohort study, adult patients who underwent pancreatic cancer surgery between 01 June 2021 and 31 June 2023 at Sahlgrenska University Hospital, Gothenburg, Sweden, and received postoperative EDA were identified using institutional electronic health records. Total daily opioid consumption (oral morphine equivalent daily dose, OMEDD) and non-opioid pharmacological treatments were characterized. Factors associated with opioid consumption on day 0 were determined using multivariable linear regression. Variable importance analysis based on R 2 decomposition (Lindeman–Merenda–Gold method) was performed. Results: A total of 194 patients were included. Median OMEDD (IQR) was 98 (60–142) mg on day 0, 75 (60–105) mg on day 1, and 60 (45–90) mg on day 2. EDA duration, age, epidural infusion rates, and preoperative opioid use were independently associated with opioid consumption at EDA discontinuation. Preoperatively confirmed malignancy and EDA analgesic failure showed potential associations. The final model explained 20.8 % of the variance in opioid consumption (adjusted R 2 =0.208). Conclusions: The transition from EDA to oral analgesia after pancreatic surgery is accompanied by high opioid consumption. In this cohort, longer EDA treatment, younger age, higher epidural infusion rates, and preoperative opioid use were associated with increased opioid consumption at EDA discontinuation, suggesting that patients at risk of high opioid usage may be identified in advance and could benefit from tailored, multimodal opioid-sparing strategies.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Scandinavian Journal of Pain
- Vol. 26 (1)
Open AccessAnalgesic patterns and predictors of opioid consumption following epidural analgesia discontinuation after pancreatic cancer surgery
Introduction: Thoracic epidural analgesia (EDA) is recommended for multimodal perioperative pain management. However, increased pain and opioid consumption are frequently observed following EDA discontinuation. Risk factors for this transition phase remain poorly characterized after pancreatic surgery. Aim: The primary aim was to characterize analgesic strategies, including opioid consumption and use of non-opioid agents, following EDA discontinuation after pancreatic cancer surgery (days 0–2). The secondary aim was to determine predictors of increased opioid consumption on the day of EDA discontinuation (day 0). Methods: In this retrospective cohort study, adult patients who underwent pancreatic cancer surgery between 01 June 2021 and 31 June 2023 at Sahlgrenska University Hospital, Gothenburg, Sweden, and received postoperative EDA were identified using institutional electronic health records. Total daily opioid consumption (oral morphine equivalent daily dose, OMEDD) and non-opioid pharmacological treatments were characterized. Factors associated with opioid consumption on day 0 were determined using multivariable linear regression. Variable importance analysis based on R 2 decomposition (Lindeman–Merenda–Gold method) was performed. Results: A total of 194 patients were included. Median OMEDD (IQR) was 98 (60–142) mg on day 0, 75 (60–105) mg on day 1, and 60 (45–90) mg on day 2. EDA duration, age, epidural infusion rates, and preoperative opioid use were independently associated with opioid consumption at EDA discontinuation. Preoperatively confirmed malignancy and EDA analgesic failure showed potential associations. The final model explained 20.8 % of the variance in opioid consumption (adjusted R 2 =0.208). Conclusions: The transition from EDA to oral analgesia after pancreatic surgery is accompanied by high opioid consumption. In this cohort, longer EDA treatment, younger age, higher epidural infusion rates, and preoperative opioid use were associated with increased opioid consumption at EDA discontinuation, suggesting that patients at risk of high opioid usage may be identified in advance and could benefit from tailored, multimodal opioid-sparing strategies.
- Open Access
- 30 October 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (6)
Classification of postoperative pancreatic fistula after left pancreatectomy: international multicentre cohort study
Background: Postoperative pancreatic fistula (POPF) is a major complication after left pancreatectomy. The current International Study Group of Pancreatic Surgery classification has limitations, including heterogeneity in morbidity and high interobserver variability. This study aimed to assess POPF-related morbidity after left pancreatectomy and propose a refined classification system. Methods: Patients undergoing left pancreatectomy at nine high-volume centres between January 2010 and April 2023 were included. All postoperative treatments and interventions related to POPF were collected. The Comprehensive Complication Index (CCI) was used to assess total cumulative morbidity. The International Study Group of Pancreatic Surgery B POPF was subclassified (B1 = prolonged drainage, B2 = pharmacological intervention, B3 = percutaneous intervention, B4 = endoscopic or angiographic intervention). A new POPF grading system was developed by combining subclasses with similar morbidity. Results: Among 2284 patients, 497 (21.8%) had B (B1: 48 (2.1%), B2: 135 (5.9%), B3: 175 (7.7%), B4: 99 (4.3%)) or C (40 (1.8%)) POPF. Median (interquartile range) POPF-related CCI was 33.5 (22.6–39.7). A significant overlap existed between B and C POPF in terms of CCI. Median CCI (i.q.r.) increased with the B POPF subclasses (B1–B4), 8.7 (8.7-8.7) – 22.6 (20.9-22.6) – 33.5 (33.5-34.6) – 47.4 (39.7-52.1) (P < 0.001), but no difference between B4 POPF and C POPF was observed (median CCI 47.4 versus 50.2; P = 0.265). The refined POPF grading system consists of grades 0 (including biochemical leak and B1), A (including B2), B (including B3), and C (including B4 and C) reflecting worsening morbidity. Conclusion: The current International Study Group of Pancreatic Surgery classification includes highly heterogeneous grade B POPF cases, ranging from minimal to severe morbidity. The refined grading system improves classification and clinical relevance by aligning POPF severity with morbidity and short-term outcomes.
- 30 October 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (6)
Open AccessClassification of postoperative pancreatic fistula after left pancreatectomy: international multicentre cohort study
Background: Postoperative pancreatic fistula (POPF) is a major complication after left pancreatectomy. The current International Study Group of Pancreatic Surgery classification has limitations, including heterogeneity in morbidity and high interobserver variability. This study aimed to assess POPF-related morbidity after left pancreatectomy and propose a refined classification system. Methods: Patients undergoing left pancreatectomy at nine high-volume centres between January 2010 and April 2023 were included. All postoperative treatments and interventions related to POPF were collected. The Comprehensive Complication Index (CCI) was used to assess total cumulative morbidity. The International Study Group of Pancreatic Surgery B POPF was subclassified (B1 = prolonged drainage, B2 = pharmacological intervention, B3 = percutaneous intervention, B4 = endoscopic or angiographic intervention). A new POPF grading system was developed by combining subclasses with similar morbidity. Results: Among 2284 patients, 497 (21.8%) had B (B1: 48 (2.1%), B2: 135 (5.9%), B3: 175 (7.7%), B4: 99 (4.3%)) or C (40 (1.8%)) POPF. Median (interquartile range) POPF-related CCI was 33.5 (22.6–39.7). A significant overlap existed between B and C POPF in terms of CCI. Median CCI (i.q.r.) increased with the B POPF subclasses (B1–B4), 8.7 (8.7-8.7) – 22.6 (20.9-22.6) – 33.5 (33.5-34.6) – 47.4 (39.7-52.1) (P < 0.001), but no difference between B4 POPF and C POPF was observed (median CCI 47.4 versus 50.2; P = 0.265). The refined POPF grading system consists of grades 0 (including biochemical leak and B1), A (including B2), B (including B3), and C (including B4 and C) reflecting worsening morbidity. Conclusion: The current International Study Group of Pancreatic Surgery classification includes highly heterogeneous grade B POPF cases, ranging from minimal to severe morbidity. The refined grading system improves classification and clinical relevance by aligning POPF severity with morbidity and short-term outcomes.
- Open Access
- 4 March 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (3)
International multicentre validation of the left pancreatectomy pancreatic fistula prediction models and development and validation of the combined DISPAIR-FRS prediction model
Background: Every fifth patient undergoing left pancreatectomy develops a postoperative pancreatic fistula (POPF). Accurate POPF risk prediction could help. Two independent preoperative prediction models have been developed and externally validated: DISPAIR and D-FRS. The aim of this study was to validate, compare, and possibly update the models. Methods: Patients from nine high-volume pancreatic surgery centres (8 in Europe and 1 in North America) were included in this retrospective cohort study. Inclusion criteria were age over 18 years and open or minimally invasive left pancreatectomy since 2010. Model performance was assessed with discrimination (receiver operating characteristic (ROC) curves) and calibration (calibration plots). The updated model was developed with logistic regression and internally-externally validated. Results: Of 2284 patients included, 497 (21.8%) developed POPF. Both DISPAIR (area under the ROC curve (AUC) 0.62) and D-FRS (AUC 0.62) performed suboptimally, both in the pooled validation cohort combining every centre’s data and centre-wise. An updated model, named DISPAIR-FRS, was constructed by combining the most stable predictors from the existing models and incorporating other readily available patient demographics, such as age, sex, transection site, pancreatic thickness at the transection site, and main pancreatic duct diameter at the transection site. Internal-external validation demonstrated an AUC of 0.72, a calibration slope of 0.93, and an intercept of −0.02 for the updated model. Conclusion: The combined updated model of DISPAIR and D-FRS named DISPAIR-FRS demonstrated better performance and can be accessed at www.tinyurl.com/the-dispair-frs.
- 4 March 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (3)
Open AccessInternational multicentre validation of the left pancreatectomy pancreatic fistula prediction models and development and validation of the combined DISPAIR-FRS prediction model
Background: Every fifth patient undergoing left pancreatectomy develops a postoperative pancreatic fistula (POPF). Accurate POPF risk prediction could help. Two independent preoperative prediction models have been developed and externally validated: DISPAIR and D-FRS. The aim of this study was to validate, compare, and possibly update the models. Methods: Patients from nine high-volume pancreatic surgery centres (8 in Europe and 1 in North America) were included in this retrospective cohort study. Inclusion criteria were age over 18 years and open or minimally invasive left pancreatectomy since 2010. Model performance was assessed with discrimination (receiver operating characteristic (ROC) curves) and calibration (calibration plots). The updated model was developed with logistic regression and internally-externally validated. Results: Of 2284 patients included, 497 (21.8%) developed POPF. Both DISPAIR (area under the ROC curve (AUC) 0.62) and D-FRS (AUC 0.62) performed suboptimally, both in the pooled validation cohort combining every centre’s data and centre-wise. An updated model, named DISPAIR-FRS, was constructed by combining the most stable predictors from the existing models and incorporating other readily available patient demographics, such as age, sex, transection site, pancreatic thickness at the transection site, and main pancreatic duct diameter at the transection site. Internal-external validation demonstrated an AUC of 0.72, a calibration slope of 0.93, and an intercept of −0.02 for the updated model. Conclusion: The combined updated model of DISPAIR and D-FRS named DISPAIR-FRS demonstrated better performance and can be accessed at www.tinyurl.com/the-dispair-frs.
- Open Access
- 20 January 2021
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 108 (3) , 265-270
Reinforced versus standard stapler transection on postoperative pancreatic fistula in distal pancreatectomy: multicentre randomized clinical trial
Postoperative pancreatic fistula is the leading cause of morbidity after distal pancreatectomy. Strategies investigated to reduce the incidence have been disappointing. Recent data showed a reduction in postoperative pancreatic fistula with the use of synthetic mesh reinforcement of the staple line. An RCT was conducted between May 2014 and February 2016 at four tertiary referral centres in Sweden. Patients scheduled for distal pancreatectomy were eligible. Enrolled patients were randomized during surgery to stapler transection with biological reinforcement or standard stapler transection. Patients were blinded to the allocation. The primary endpoint was the development of any postoperative pancreatic fistula. Secondary endpoints included morbidity, mortality, and duration of hospital stay. Some 107 patients were randomized and 106 included in an intention-to-treat analysis (56 in reinforced stapling group, 50 in standard stapling group). No difference was demonstrated in terms of clinically relevant fistulas (grade B and C): 6 of 56 (11 per cent) with reinforced stapling versus 8 of 50 (16 per cent) with standard stapling (P = 0.332). There was no difference between groups in overall postoperative complications: 45 (80 per cent) and 39 (78 per cent) in reinforced and standard stapling groups respectively (P = 0.765). Duration of hospital stay was comparable: median 8 (range 2–35) and 9 (2–114) days respectively (P = 0.541). Biodegradable stapler reinforcement at the transection line of the pancreas did not reduce postoperative pancreatic fistula compared with regular stapler transection in distal pancreatectomy. Registration number: NCT02149446 (http://www.clinicaltrials.gov).
- 20 January 2021
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 108 (3) , 265-270
Open AccessReinforced versus standard stapler transection on postoperative pancreatic fistula in distal pancreatectomy: multicentre randomized clinical trial
Postoperative pancreatic fistula is the leading cause of morbidity after distal pancreatectomy. Strategies investigated to reduce the incidence have been disappointing. Recent data showed a reduction in postoperative pancreatic fistula with the use of synthetic mesh reinforcement of the staple line. An RCT was conducted between May 2014 and February 2016 at four tertiary referral centres in Sweden. Patients scheduled for distal pancreatectomy were eligible. Enrolled patients were randomized during surgery to stapler transection with biological reinforcement or standard stapler transection. Patients were blinded to the allocation. The primary endpoint was the development of any postoperative pancreatic fistula. Secondary endpoints included morbidity, mortality, and duration of hospital stay. Some 107 patients were randomized and 106 included in an intention-to-treat analysis (56 in reinforced stapling group, 50 in standard stapling group). No difference was demonstrated in terms of clinically relevant fistulas (grade B and C): 6 of 56 (11 per cent) with reinforced stapling versus 8 of 50 (16 per cent) with standard stapling (P = 0.332). There was no difference between groups in overall postoperative complications: 45 (80 per cent) and 39 (78 per cent) in reinforced and standard stapling groups respectively (P = 0.765). Duration of hospital stay was comparable: median 8 (range 2–35) and 9 (2–114) days respectively (P = 0.541). Biodegradable stapler reinforcement at the transection line of the pancreas did not reduce postoperative pancreatic fistula compared with regular stapler transection in distal pancreatectomy. Registration number: NCT02149446 (http://www.clinicaltrials.gov).
- 21 December 2017
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (2) , 225-230
Lymph node 8a as a prognostic marker for poorer prognosis in pancreatic and periampullary carcinoma
Objectives: An investigation of patients with pancreatic carcinoma aims to identify those who will benefit from surgery. Physical examination, radiology and laboratory findings are helpful. Most prognostic markers, such as lymph node status, micro metastasis and tumour differentiation, are not preoperatively accessible. Metastatic disease in lymph node 8a (Ln8a) in patients operated for pancreatic carcinoma has been reported to be a predictor of shorter overall survival (OS). This lymph node can be assessed preoperatively through resection (possibly even with laparoscopy) and subsequent histopathology. The value of the procedure is disputed. The aim of this study is to investigate whether metastatic disease in Ln8a is a predictor of decreased OS. Materials and methods: In patients with suspected pancreatic or periampullary carcinoma, who were operated with pancreatoduodenectomy (PD), Ln8a was separately resected and analysed with standard and immuno-histochemical methods. Patients with or without metastasis in Ln8a were compared regarding OS. Results: Between 2008 and 2011, 122 consecutive patients were eligible and 87 were resected and had LN8a analysed separately. Sixteen patients were Ln8a + and 71 were Ln8a-. Patients with Ln8a + had a significantly reduced median OS as compared to patients with Ln8a– (0.74 (95% CI 0.26–1.26) versus 5.91 years (95% CI 2.91–), p < .001). Conclusion: Ln8a + was associated with a marked reduction of OS, indicating a possible role in the future preoperative workup in patients with a suspicion of pancreatic cancer.
- 21 December 2017
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (2) , 225-230
Lymph node 8a as a prognostic marker for poorer prognosis in pancreatic and periampullary carcinoma
Objectives: An investigation of patients with pancreatic carcinoma aims to identify those who will benefit from surgery. Physical examination, radiology and laboratory findings are helpful. Most prognostic markers, such as lymph node status, micro metastasis and tumour differentiation, are not preoperatively accessible. Metastatic disease in lymph node 8a (Ln8a) in patients operated for pancreatic carcinoma has been reported to be a predictor of shorter overall survival (OS). This lymph node can be assessed preoperatively through resection (possibly even with laparoscopy) and subsequent histopathology. The value of the procedure is disputed. The aim of this study is to investigate whether metastatic disease in Ln8a is a predictor of decreased OS. Materials and methods: In patients with suspected pancreatic or periampullary carcinoma, who were operated with pancreatoduodenectomy (PD), Ln8a was separately resected and analysed with standard and immuno-histochemical methods. Patients with or without metastasis in Ln8a were compared regarding OS. Results: Between 2008 and 2011, 122 consecutive patients were eligible and 87 were resected and had LN8a analysed separately. Sixteen patients were Ln8a + and 71 were Ln8a-. Patients with Ln8a + had a significantly reduced median OS as compared to patients with Ln8a– (0.74 (95% CI 0.26–1.26) versus 5.91 years (95% CI 2.91–), p < .001). Conclusion: Ln8a + was associated with a marked reduction of OS, indicating a possible role in the future preoperative workup in patients with a suspicion of pancreatic cancer.